Cite

    Paul G Richardson et al.. “Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study.” Lancet, vol. 2, no. 12, 2015, pp. e516–e527. http://access.bl.uk/ark:/81055/vdc_100066540009.0x000007